ReviewOne health (Amsterdam, Netherlands)2026
Genetic insights into hepatitis E virus through environmental surveillance in Europe.
Review in One health (Amsterdam, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hepatitis E virus infection: considerations for immunologists and rheumatologists.Rheumatology international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zoonotic hepatitis E has been a growing public health concern in Europe, but the transmission of its causative agent, hepatitis E virus (HEV), remains incompletely understood. Environmental surveillance, particularly through wastewater monitoring, has proven valuable for tracking viral circulation and variant shift during the COVID-19 pandemic, yet its application to HEV is still limited. In this review, we systematically analyzed HEV sequences across Europe, focusing on environmental sources from a genetic perspective. Of more than 13,100 HEV sequences deposited in the NCBI database, only 2.4 % (316/13,118) originated from environmental samples, including wastewater, surface water, and biosolids. Additional typing data from the literature revealed highly uneven geographic distribution, with 97 % of environmental sequences reported from Italy, France, the United Kingdom (UK), Spain, Sweden, and Germany. HEV-3 was the dominant genotype, while HEV-1 and HEV-4 were occasionally detected. Subtypes 3c and 3f were most common, but their prevalence varied across countries and sample types. Some countries, such as France, Sweden, and the UK, exhibited divergent subtype patterns between humans, animals, and environmental sources, whereas others, such as Spain and Germany, showed more consistent distributions. These findings highlight the importance of integrating clinical, veterinary, and environmental surveillance to better understand HEV transmission in Europe under a One Health framework. However, the scarcity of environmental data, technical challenges in sequencing, and lack of standardized protocols limit comprehensive assessment of HEV circulation. Expanding sequencing efforts, improving detection methods, and coordinating international surveillance frameworks will be critical to strengthen HEV monitoring and preparedness against emerging HEV threats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.